ClinicalTrials.gg
Not yet recruitingNCT06438458Updated Jun 3, 2024

Effect of Postural Change on Hemoglobin Level in Patients on the Intensive Care Unit

An interventional study of Postural change from supine to sitting and Mobilization to a chair in Anemia, sponsored by Deventer Ziekenhuis. Not yet recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-03.

Sponsored by Deventer Ziekenhuis · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 47 studies in Anemia with a site in Netherlands — 5 open to participants now, 10 under way, 7 of them phase 3. Anemia · Netherlands.

Planned enrollment
33rd of 38
24 · median 219
Started
2024
with 2 others
No phase
5 of 47
2 open now
Registered
43rd of 47
by date

Among the 47 studies in Anemia with a site in Netherlands, this one is the 33rd largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2024, is one of 5 with no phase, and was the 43rd registered.

Anemia

1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.

Browse Anemia studies →

Open to participants now

5 of the 47 studies in Anemia with a site in Netherlands are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Anemia with a site in Netherlands, or all of them as a file.
02

Study summary

Monitoring hemoglobin levels (Hb) is important to identify anemia in hospitalized patients. Changes in posture and mobilization efforts, as demonstrated by previous research, can lead to significant shifts in Hb concentrations. This phenomenon has not been studied in ICU patients.

This study aims to investigate whether postural changes and mobilisation affect Hb in ICU patients. We hypothesize that significant Hb shifts may occur, potentially leading to misinterpretations of anemia and unnecessary diagnostic and therapeutic workup. Understanding this impact can guide clinical practice and prevent unwarranted interventions.

Read the detailed description

Rationale:

Monitoring hemoglobin levels (Hb) is important to identify anemia in hospitalized patients. Changes in posture and mobilization efforts, as demonstrated by previous research, can lead to significant shifts in Hb concentrations. Low Hb levels due to these shifts are termed 'postural pseudoanemia'.

This phenomenon has not been studied in ICU patients. Many factors may affect Hb concentrations in ICU patients, including plasma volume shifts, bleeding, repeated phlebotomies, hemolysis, bone marrow suppression and functional iron deficiency. When this leads to significant anemia, patients may be treated with red blood cell transfusions. However, blood transfusions have been associated with adverse reactions and should only be performed for appropriate indications. If postural pseudoanemia occurs in ICU patients this could lead to patient harm through inadvertent investigations and red blood cell transfusions. The occurrence of postural pseudoanemia in ICU patients may differ from previous studies because ICU patients are more frequently immobilized for more prolonged periods.

This study aims to investigate whether postural changes affect Hb in ICU patients. We hypothesize that significant Hb shifts may occur, potentially leading to misinterpretations of anemia and unnecessary diagnostic and therapeutic workup. Understanding this impact can guide clinical practice and prevent unwarranted interventions.

Objective:

Main objective: To assess Hb levels in ICU patients upon a change in posture from supine to upright and following mobilization to a chair.

Secondary objectives:

To seek correlations between hemoglobin shifts and changes in serum albumin concentrations upon a change in posture from supine to sitting and following mobilization to a chair.

To seek correlations between hemoglobin shifts and changes in serum uric acid concentrations upon a change in posture from supine to sitting and following mobilization to a chair.

To seek correlations between hemoglobin shifts and levels of CRP and ESR upon a change in posture from supine to sitting and following mobilization to a chair.

To compare hemoglobin concentrations following > 6 hours in supine position at 24 hours with pre-intervention levels for patients remaining in the ICU.

Any other changes seen in the lab measurements or vital parameters upon a change in posture?

Study design:

Prospective uncontrolled interventional study.

Study population:

Patients > 18 years old, admitted to the intensive care unit.

Intervention:

All patients will undergo a change in posture from supine to upright, followed by mobilization to a chair.

Main study parameters/endpoints:

Relative percentage change in Hb.

03

Conditions studied

  • Anemia

Browse trials for

Keywords

  • Blood composition
  • Circulatory physiology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 18 years, of any gender and ethnic background
  • Admitted to the intensive care unit
  • Able to give
  • Patients with an arterial line as part of their treatment plan.
  • Patients able to remain seated in chair for at least 30 minutes
  • Patients able to remain supine overnight for at least 6 hours

Exclusion criteria

Exclusion Criteria:

  • Delirium or inability to give
  • Inability to understand written information in Dutch
  • Patients on artificial ventilation
  • Orotracheally intubated patients (spontaneous breathing through a tracheostomy cannula is allowed)
  • Patients treated with noradrenaline > 0.05 ug/kg/min
  • Patients treated with argipressin
  • Patients who received a blood transfusion within 24 hours before measurements
  • Patients who received > 3 L of fluids within 24 hours before measurements
  • Patients who received > 500 ml of iv fluids within 4 hours of measurements
  • Severe restlessness or inability to remain supine for 6 hours before initial blood sampling
  • Patients being treated with diuretics
  • Patients admitted with:
  • Decompensated right heart failure
  • Pulmonary hypertension
  • Pulmonary embolism
  • Active bleeding or risk of >100 ml blood loss
  • Hematological disorder/
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Hb in different positions

    Hemoglobin concentration after sitting in bed (passively) for \>30 min, and after mobilization to a chair for \>30 min

    Procedure: Postural change from supine to sitting · Procedure: Mobilization to a chair

Interventions

  • ProcedurePostural change from supine to sitting

    Patients go from supine to sitting position in bed (passive)

  • ProcedureMobilization to a chair

    Patients go from the bed to sitting in a chair (active)

06

What researchers measure

Primary outcomes

  1. Hemoglobin

    Hemoglobin concentration

    Time frame: 3 hours

Secondary outcomes

  1. Albumin

    Albumin concentration

    Time frame: 3 hours

Other outcomes

  1. Uric acid

    Uric acid concentration

    Time frame: 3 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Data can be obtained from the principal investigator upon request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: After preparation of the manuscript.

Access criteria: A written request must be sent to the principal investigator.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2024; primary completion for Oct 2024, 4 months later.

Of 165 non-industry interventional studies with no phase under Anemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 30. This study's planned 4 months is below that.

Counting every sponsor, half of 179 studies reached it within 17 months; a quarter within 7 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2024
First posted
Jun 3, 2024
StartEst.
Jun 17, 2024
Primary completionEst.
Oct 30, 2024
CompletionEst.
Oct 30, 2024
Last update
Jun 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06438458
Lead sponsor
Deventer Ziekenhuis
Responsible party
Sponsor
First posted
Jun 3, 2024
Start date
Jun 17, 2024 (estimated)
Primary completion
Oct 30, 2024 (estimated)
Completion
Oct 30, 2024 (estimated)
Last update
Jun 3, 2024

Study contacts

Alfred L van Steveninck, M.D., Ph.D.
Contact
f.steveninckvan@dz.nl
+31570535346
Huub LA van den Oever, M.D.
Contact
h.vandenoever@dz.nl
+31570535346
Alfred L van Steveninck, M.D., Ph.D.
principal investigator · Deventer Ziekenhuis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion